AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

Quest Diagnostics Incorporated

$235.02 +$61.23 (+35.23%)
NYSE · 11 Sep 2026 20:00 UTC
Previous Close
$231.14
Day Range
$229.33$235.12
Year Range
$171.18$247.19
Market Cap
25.94B
AVG Volume
906.73K
Trailing/Forward PE
24.64/19.49
PEG ratio
3.18
Dividend Yield
1.41%
Next Earnings Date
2026-10-20
Primary Exchange
New York Stock ExchangeUS
Revenue (USD) · TTM
05B10B15B24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
DGX Revenue (USD) · TTM by quarter
PeriodRevenue (USD) · TTM
26 Q211.56B
26 Q111.28B
25 Q411.04B
25 Q310.85B
25 Q210.52B
25 Q110.16B
24 Q49.87B
24 Q39.54B
24 Q29.35B
24 Q19.29B
Net Income (USD) · TTM
0500M1B1.5B24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
DGX Net Income (USD) · TTM by quarter
PeriodNet Income (USD) · TTM
26 Q21.06B
26 Q11.02B
25 Q4992M
25 Q3969M
25 Q2950M
25 Q1897M
24 Q4871M
24 Q3841M
24 Q2840M
24 Q1846M
Operating Income (USD) · TTM
0500M1B1.5B2B24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
DGX Operating Income (USD) · TTM by quarter
PeriodOperating Income (USD) · TTM
26 Q21.64B
26 Q11.61B
25 Q41.56B
25 Q31.53B
25 Q21.48B
25 Q11.39B
24 Q41.35B
24 Q31.25B
24 Q21.26B
24 Q11.26B
EBITDA (USD) · TTM
01B2B3B24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
DGX EBITDA (USD) · TTM by quarter
PeriodEBITDA (USD) · TTM
26 Q22.01B
26 Q12.12B
25 Q42.18B
25 Q32.14B
25 Q22.07B
25 Q11.95B
24 Q41.9B
24 Q31.78B
24 Q21.75B
24 Q11.74B
Cash Flows (USD) · TTM
0500M1B1.5B24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
DGX Cash Flows (USD) · TTM by quarter
PeriodCash Flows (USD) · TTM
26 Q21.22B
26 Q11.33B
25 Q41.36B
25 Q31.39B
25 Q21.22B
25 Q11.06B
24 Q4909M
24 Q31.02B
24 Q2875M
24 Q1947M
EPS (USD) · TTM
02.557.51024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
DGX EPS (USD) · TTM by quarter
PeriodEPS (USD) · TTM
26 Q29.42
26 Q19.05
25 Q48.75
25 Q38.52
25 Q28.35
25 Q17.92
24 Q47.7
24 Q37.45
24 Q27.42
24 Q17.43
Expenses (USD) · TTM
01B2B3BSG&ACapex24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
DGX Expenses (USD) · TTM by quarter
PeriodExpenses (USD) · TTM
26 Q22.57B
26 Q12.5B
25 Q42.48B
25 Q32.42B
25 Q22.33B
25 Q12.23B
24 Q42.18B
24 Q32.07B
24 Q22B
24 Q12.02B
Shares Outstanding (USD) · TTM
-200M0200M400M600MBuybacks (Repurchases)Stock-Based Compensation24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
DGX Shares Outstanding (USD) · TTM by quarter
PeriodShares Outstanding (USD) · TTM
26 Q2489M
26 Q1389M
25 Q4387M
25 Q3211M
25 Q262M
25 Q163M
24 Q463M
24 Q3195M
24 Q2196M
24 Q1200M
Dividends (USD)
00.250.50.751Jul 24Oct 24Jan 25Apr 25Jul 25Oct 25Jan 26Apr 26Jul 26Oct 26
DGX Dividends (USD) by quarter
PeriodDividends (USD)
Oct 260.86
Jul 260.86
Apr 260.86
Jan 260.8
Oct 250.8
Jul 250.8
Apr 250.8
Jan 250.75
Oct 240.75
Jul 240.75
Employee Count
020K40K60K2016201720182019202020212022202320242025
DGX Employee Count by quarter
PeriodEmployee Count
202557K
202456K
202340K
202240K
202140K
202040K
201947K
201846K
201745K
201643K
PE Ratio
1820222426med 21.57Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
DGX PE Ratio by quarter
PeriodPE Ratio
Sep 2624.34
Sep 2624.56
Aug 2625.14
Aug 2625.31
Aug 2624.28
Aug 2624.69
Jul 2624.13
Jul 2623.6
Jul 2622.63
Jul 2622.28
Jul 2623.17
Jun 2622.55
Jun 2620.95
Jun 2621.81
Jun 2621.52
May 2620.94
May 2620.97
May 2620.05
May 2620.13
May 2620.7
Apr 2621.08
Apr 2621.82
Apr 2621.43
Apr 2622.16
Mar 2621.88
Mar 2621.85
Mar 2622.35
Mar 2622.29
Feb 2623.71
Feb 2623.4
Feb 2623.91
Feb 2622.04
Jan 2621.62
Jan 2620.92
Jan 2621.9
Jan 2620.16
Jan 2620.09
Dec 2520.34
Dec 2520.35
Dec 2521.1
Dec 2521.1
Nov 2521.87
Nov 2522.11
Nov 2521.61
Nov 2520.75
Oct 2520.34
Oct 2521.06
Oct 2522.34
Oct 2521.7
Oct 2521.14
Sep 2522.28
Sep 2521.65
Sep 2521.56
Sep 2521.63
Aug 2521.41
Aug 2521.25
Aug 2521.19
Aug 2520.86
Aug 2520.14
Jul 2519.87
Jul 2520.65
Jul 2520.8
Jul 2521.89
Jun 2522.01
Jun 2522.2
Jun 2522.3
Jun 2521.57
May 2521.45
May 2521.19
May 2522.02
May 2521.9
May 2522.02
Apr 2521.5
Apr 2520.87
Apr 2520.9
Apr 2520.92
Mar 2521.32
Mar 2521.3
Mar 2521.69
Mar 2522.37
Feb 2522.03
Feb 2521.95
Feb 2522.48
Feb 2521.66
Jan 2521.72
Jan 2520.68
Jan 2520.14
Jan 2520.21
Jan 2520.23
Dec 2420.33
Dec 2420.39
Dec 2420.64
Dec 2420.96
Nov 2421.66
Nov 2421.79
Nov 2421.37
Nov 2421.22
Nov 2420.68
Oct 2420.65
Oct 2419.78
Free Cash Flow Yield
4%5%6%7%8%med 5.91%Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
DGX Free Cash Flow Yield by quarter
PeriodFree Cash Flow Yield
Sep 264.72%
Sep 264.68%
Aug 264.57%
Aug 264.54%
Aug 264.73%
Aug 264.65%
Jul 264.76%
Jul 264.87%
Jul 265.72%
Jul 265.81%
Jul 265.59%
Jun 265.74%
Jun 266.18%
Jun 265.94%
Jun 266.02%
May 266.18%
May 266.18%
May 266.46%
May 266.43%
May 266.26%
Apr 266.14%
Apr 266.28%
Apr 266.39%
Apr 266.18%
Mar 266.26%
Mar 266.27%
Mar 266.13%
Mar 266.15%
Feb 265.78%
Feb 266.14%
Feb 266.01%
Feb 266.52%
Jan 266.65%
Jan 266.87%
Jan 266.56%
Jan 267.13%
Jan 267.16%
Dec 257.07%
Dec 257.06%
Dec 256.81%
Dec 256.81%
Nov 256.57%
Nov 256.5%
Nov 256.65%
Nov 256.93%
Oct 257.07%
Oct 256.83%
Oct 255.77%
Oct 255.94%
Oct 256.09%
Sep 255.78%
Sep 255.95%
Sep 255.97%
Sep 255.96%
Aug 256.02%
Aug 256.06%
Aug 256.08%
Aug 256.18%
Aug 256.4%
Jul 256.48%
Jul 255.7%
Jul 255.66%
Jul 255.38%
Jun 255.35%
Jun 255.3%
Jun 255.28%
Jun 255.46%
May 255.49%
May 255.56%
May 255.35%
May 255.38%
May 255.35%
Apr 255.48%
Apr 255%
Apr 254.99%
Apr 254.99%
Mar 254.89%
Mar 254.9%
Mar 254.81%
Mar 254.66%
Feb 254.74%
Feb 254.75%
Feb 255.41%
Feb 255.62%
Jan 255.6%
Jan 255.88%
Jan 256.04%
Jan 256.02%
Jan 256.01%
Dec 245.98%
Dec 245.97%
Dec 245.89%
Dec 245.8%
Nov 245.62%
Nov 245.58%
Nov 245.69%
Nov 245.73%
Nov 245.88%
Oct 245.89%
Oct 245.27%
Price to Sales
1.61.822.22.4med 1.92Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
DGX Price to Sales by quarter
PeriodPrice to Sales
Sep 262.24
Sep 262.26
Aug 262.31
Aug 262.33
Aug 262.23
Aug 262.27
Jul 262.22
Jul 262.17
Jul 262.05
Jul 262.02
Jul 262.1
Jun 262.05
Jun 261.9
Jun 261.98
Jun 261.95
May 261.9
May 261.9
May 261.82
May 261.83
May 261.88
Apr 261.91
Apr 261.96
Apr 261.93
Apr 261.99
Mar 261.97
Mar 261.96
Mar 262.01
Mar 262
Feb 262.13
Feb 262.09
Feb 262.14
Feb 261.97
Jan 261.93
Jan 261.87
Jan 261.96
Jan 261.8
Jan 261.79
Dec 251.82
Dec 251.82
Dec 251.88
Dec 251.88
Nov 251.95
Nov 251.97
Nov 251.93
Nov 251.85
Oct 251.82
Oct 251.88
Oct 252.02
Oct 251.96
Oct 251.91
Sep 252.01
Sep 251.95
Sep 251.95
Sep 251.95
Aug 251.93
Aug 251.92
Aug 251.91
Aug 251.88
Aug 251.82
Jul 251.79
Jul 251.82
Jul 251.84
Jul 251.93
Jun 251.94
Jun 251.96
Jun 251.97
Jun 251.91
May 251.89
May 251.87
May 251.94
May 251.93
May 251.94
Apr 251.9
Apr 251.84
Apr 251.84
Apr 251.85
Mar 251.88
Mar 251.88
Mar 251.91
Mar 251.97
Feb 251.94
Feb 251.94
Feb 251.98
Feb 251.91
Jan 251.92
Jan 251.82
Jan 251.78
Jan 251.78
Jan 251.78
Dec 241.79
Dec 241.8
Dec 241.82
Dec 241.85
Nov 241.91
Nov 241.92
Nov 241.88
Nov 241.87
Nov 241.82
Oct 241.82
Oct 241.78
EV/EBITDA
1012141618med 13.15Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
DGX EV/EBITDA by quarter
PeriodEV/EBITDA
Sep 2615.74
Sep 2615.86
Aug 2616.17
Aug 2616.25
Aug 2615.71
Aug 2615.92
Jul 2615.63
Jul 2615.35
Jul 2614.02
Jul 2613.85
Jul 2614.28
Jun 2613.98
Jun 2613.21
Jun 2613.62
Jun 2613.48
May 2613.2
May 2613.22
May 2612.77
May 2612.81
May 2613.09
Apr 2613.27
Apr 2612.93
Apr 2612.75
Apr 2613.08
Mar 2612.95
Mar 2612.94
Mar 2613.17
Mar 2613.14
Feb 2613.79
Feb 2613.39
Feb 2613.62
Feb 2612.77
Jan 2612.58
Jan 2612.27
Jan 2612.71
Jan 2611.92
Jan 2611.89
Dec 2512
Dec 2512.01
Dec 2512.35
Dec 2512.34
Nov 2512.69
Nov 2512.8
Nov 2512.58
Nov 2512.19
Oct 2512
Oct 2512.33
Oct 2513.18
Oct 2512.89
Oct 2512.63
Sep 2513.16
Sep 2512.86
Sep 2512.83
Sep 2512.86
Aug 2512.76
Aug 2512.68
Aug 2512.66
Aug 2512.5
Aug 2512.17
Jul 2512.05
Jul 2512.76
Jul 2512.83
Jul 2513.33
Jun 2513.38
Jun 2513.47
Jun 2513.52
Jun 2513.18
May 2513.13
May 2513.01
May 2513.39
May 2513.33
May 2513.39
Apr 2513.15
Apr 2512.96
Apr 2512.97
Apr 2512.98
Mar 2513.17
Mar 2513.15
Mar 2513.33
Mar 2513.65
Feb 2513.49
Feb 2513.45
Feb 2514.11
Feb 2513.72
Jan 2513.75
Jan 2513.26
Jan 2513
Jan 2513.04
Jan 2513.05
Dec 2413.09
Dec 2413.12
Dec 2413.24
Dec 2413.39
Nov 2413.72
Nov 2413.78
Nov 2413.58
Nov 2413.51
Nov 2413.26
Oct 2413.24
Oct 2412.23
Price/Operating Cashflow
10121416med 12.31Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
DGX Price/Operating Cashflow by quarter
PeriodPrice/Operating Cashflow
Sep 2614.57
Sep 2614.7
Aug 2615.05
Aug 2615.15
Aug 2614.53
Aug 2614.78
Jul 2614.45
Jul 2614.13
Jul 2612.53
Jul 2612.33
Jul 2612.83
Jun 2612.48
Jun 2611.59
Jun 2612.07
Jun 2611.91
May 2611.59
May 2611.61
May 2611.1
May 2611.14
May 2611.46
Apr 2611.67
Apr 2611.48
Apr 2611.27
Apr 2611.65
Mar 2611.51
Mar 2611.49
Mar 2611.75
Mar 2611.72
Feb 2612.47
Feb 2612.03
Feb 2612.29
Feb 2611.33
Jan 2611.11
Jan 2610.76
Jan 2611.26
Jan 2610.36
Jan 2610.33
Dec 2510.45
Dec 2510.46
Dec 2510.85
Dec 2510.84
Nov 2511.24
Nov 2511.36
Nov 2511.11
Nov 2510.67
Oct 2510.45
Oct 2510.82
Oct 2512.65
Oct 2512.29
Oct 2511.97
Sep 2512.61
Sep 2512.25
Sep 2512.21
Sep 2512.25
Aug 2512.12
Aug 2512.03
Aug 2512
Aug 2511.81
Aug 2511.4
Jul 2511.25
Jul 2512.4
Jul 2512.49
Jul 2513.14
Jun 2513.21
Jun 2513.33
Jun 2513.39
Jun 2512.95
May 2512.88
May 2512.72
May 2513.22
May 2513.15
May 2513.22
Apr 2512.91
Apr 2513.63
Apr 2513.65
Apr 2513.66
Mar 2513.92
Mar 2513.9
Mar 2514.16
Mar 2514.61
Feb 2514.39
Feb 2514.33
Feb 2513.53
Feb 2513.04
Jan 2513.08
Jan 2512.45
Jan 2512.12
Jan 2512.17
Jan 2512.18
Dec 2412.24
Dec 2412.27
Dec 2412.43
Dec 2412.62
Nov 2413.04
Nov 2413.12
Nov 2412.86
Nov 2412.78
Nov 2412.45
Oct 2412.43
Oct 2413.31
Price to Book
2.252.52.7533.253.5med 2.77Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
DGX Price to Book by quarter
PeriodPrice to Book
Sep 263.31
Sep 263.34
Aug 263.42
Aug 263.44
Aug 263.3
Aug 263.35
Jul 263.28
Jul 263.21
Jul 263.02
Jul 262.98
Jul 263.1
Jun 263.01
Jun 262.8
Jun 262.91
Jun 262.87
May 262.8
May 262.8
May 262.68
May 262.69
May 262.76
Apr 262.82
Apr 262.97
Apr 262.92
Apr 263.02
Mar 262.98
Mar 262.97
Mar 263.04
Mar 263.03
Feb 263.23
Feb 263.07
Feb 263.14
Feb 262.9
Jan 262.84
Jan 262.75
Jan 262.88
Jan 262.65
Jan 262.64
Dec 252.67
Dec 252.67
Dec 252.77
Dec 252.77
Nov 252.87
Nov 252.9
Nov 252.84
Nov 252.73
Oct 252.67
Oct 252.77
Oct 252.89
Oct 252.81
Oct 252.73
Sep 252.88
Sep 252.8
Sep 252.79
Sep 252.8
Aug 252.77
Aug 252.75
Aug 252.74
Aug 252.7
Aug 252.6
Jul 252.57
Jul 252.63
Jul 252.65
Jul 252.79
Jun 252.8
Jun 252.83
Jun 252.84
Jun 252.75
May 252.73
May 252.7
May 252.8
May 252.79
May 252.8
Apr 252.74
Apr 252.64
Apr 252.64
Apr 252.64
Mar 252.69
Mar 252.69
Mar 252.74
Mar 252.83
Feb 252.78
Feb 252.77
Feb 252.73
Feb 252.63
Jan 252.64
Jan 252.51
Jan 252.45
Jan 252.46
Jan 252.46
Dec 242.47
Dec 242.48
Dec 242.51
Dec 242.55
Nov 242.63
Nov 242.65
Nov 242.6
Nov 242.58
Nov 242.51
Oct 242.51
Oct 242.47
Quest Diagnostics Incorporated
DGX
Stockpicker

Video analysis: DGX

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: DGX

Apple Health app Users to be Able to Order Labs from Quest Diagnostics

prnewswire.com · 9 Sep 2026

Apple Health app Users to be Able to Order Labs from Quest Diagnostics

Coming later this year, Apple Health app users will be able to conveniently and securely purchase and receive results of Quest's biomarker lab testing directly in the app SECAUCUS, N.J., Sept. 9, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX) today announced that Apple Health app users in the United States1 will be able to conveniently purchase a tailored Quest laboratory test panel that includes over 50 biomarkers directly through the app on iPhone and iPad later this year.

Take the Zacks Approach to Beat the Markets: Oportun Financial, Uranium Royalty & Amgen in Focus

zacks.com · 8 Sep 2026

Take the Zacks Approach to Beat the Markets: Oportun Financial, Uranium Royalty & Amgen in Focus

Zacks spotlights Oportun Financial, Uranium Royalty and Amgen, alongside standout gains from its key stock portfolios.

Connor Clark & Lunn Investment Management Ltd. Buys Shares of 3,113 Quest Diagnostics Incorporated $DGX

defenseworld.net · 1 Sep 2026

Connor Clark & Lunn Investment Management Ltd. Buys Shares of 3,113 Quest Diagnostics Incorporated $DGX

Connor Clark and Lunn Investment Management Ltd. purchased a new position in Quest Diagnostics Incorporated (NYSE: DGX) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 3,113 shares of the medical research company's stock, valued at approximately $660,000. Other

Quest Diagnostics (DGX) is a Top-Ranked Value Stock: Should You Buy?

zacks.com · 31 Aug 2026

Quest Diagnostics (DGX) is a Top-Ranked Value Stock: Should You Buy?

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Bank OZK Makes New Investment in Quest Diagnostics Incorporated $DGX

defenseworld.net · 28 Aug 2026

Bank OZK Makes New Investment in Quest Diagnostics Incorporated $DGX

Bank OZK purchased a new position in Quest Diagnostics Incorporated (NYSE: DGX) in the second quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 15,322 shares of the medical research company's stock, valued at approximately $3,247,000. Other institutional investors and hedge funds have also made changes to their

Artia Global Partners LP Acquires New Holdings in Quest Diagnostics Incorporated $DGX

defenseworld.net · 27 Aug 2026

Artia Global Partners LP Acquires New Holdings in Quest Diagnostics Incorporated $DGX

Artia Global Partners LP purchased a new stake in shares of Quest Diagnostics Incorporated (NYSE: DGX) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 65,122 shares of the medical research company's stock, valued at approximately $13,803,000. Quest Diagnostics

Quest Diagnostics to Speak at the Baird 2026 Global Healthcare Conference

prnewswire.com · 25 Aug 2026

Quest Diagnostics to Speak at the Baird 2026 Global Healthcare Conference

SECAUCUS, N.J., Aug. 25, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will speak on the company's strategy, performance and the latest market developments and trends during the Baird 2026 Global Healthcare Conference in New York City on Tuesday, September 15, 2026, at 10:50 a.m.

Humanity Brings Biological Age Analysis to the U.S. Through questhealth.com

prnewswire.com · 25 Aug 2026

Humanity Brings Biological Age Analysis to the U.S. Through questhealth.com

Individuals in the U.S. can now add Humanity Biological Age's lab-informed insights to select health profile tests purchased through Quest's consumer-initiated testing platform LONDON, Aug. 25, 2026 /PRNewswire/ -- Humanity Health Inc. ("Humanity"), the longevity science company, and Quest Diagnostics (NYSE: DGX) today announced that Humanity Biological Age, Humanity's scientifically validated model for measuring biological age from biomarker lab test results, is now available in the United States for the first time through questhealth.com, Quest's consumer-initiated testing platform. Individuals now have the option to select the Humanity Biological Age add-on when purchasing select health profile tests from questhealth.com including Elite Health Profile, Men's and Women's Comprehensive Health Profiles, and Fitness Profile — Elite, with no additional blood draw needed.

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.